Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Yufan Bio Partners with Pittsburgh's Abound to Develop Novel CAR-T Therapies

publication date: Sep 16, 2020

Yufan Bio, a Xi'an clinical-stage CAR-T company, partnered with Abound Bio of Pittsburgh to develop novel CAR-T technologies. The two companies will explore the use of HPK1 (hematopoietic progenitor kinase 1) inhibitors to make CAR-T therapies more effective. HPK1 has been shown to promote CAR-T exhaustion in research done by Xuebin Liao, PhD, Professor of Pharmaceutical Science at Tsinghua University and a Yufan co-founder. Yufan is working to inhibit HPK1 via gene knockout or small-molecule inhibitors. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020